Form 4: Neurocrine Biosciences CEO Kyle Gano Executes Stock Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Neurocrine Biosciences CEO Kyle Gano exercised stock options and sold shares of common stock on January 15, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- On January 15, 2025, Kyle Gano, the CEO of Neurocrine Biosciences, exercised incentive and non-qualified stock options.
- Gano acquired 4,812 shares and 60,188 shares through the exercise of these options at a price of $32.99 per share.
- Simultaneously, Gano sold 4,812 shares and 60,188 shares of common stock at an average price of approximately $141.50 per share.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on March 15, 2024.
- Following these transactions, Gano directly owns 135,392 shares of Neurocrine Biosciences common stock.
- The exercised options were granted on February 3, 2015, and vested in equal monthly installments starting March 3, 2015, and were set to expire on February 3, 2025.
- Gano also owns 0 derivative securities after the transaction.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating routine transactions by a company executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about stock transactions.
Industry Context
Executive stock option exercises and sales are common practice, particularly under 10b5-1 plans, which allow insiders to trade company stock while avoiding accusations of insider trading. The filing provides transparency into the transactions of a key executive at Neurocrine Biosciences.
Comparison to Industry Standards
- Executive compensation packages often include stock options as a way to align management's interests with those of shareholders.
- The use of 10b5-1 trading plans is a standard practice among corporate executives to manage their stock holdings in a compliant manner.
- The vesting schedule of the options (48 equal monthly installments) is a typical vesting arrangement.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the trades mitigates any significant concerns.
- Employees may be indirectly affected by the executive's actions, but the overall impact is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 02/03/2015 | Date incentive and non-qualified stock options were granted. |
| 03/03/2015 | Vesting of options began in 48 equal monthly installments. |
| 03/15/2024 | Date the Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 02/29/2024 | Purchase of 226 shares from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. |
| 01/15/2025 | Date of stock option exercise and sale of shares. |
| 02/03/2025 | Expiration date of the exercised stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.